Saltar al contenido
Salud cardiovascularArtículo de investigación4 min read

Blood pressure swings predicted heart events beyond the average

Colectivo editorial MoveVitals · Study published · Reading updated

Original paper:Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial. · European heart journal · 2024 · Artículo original ↗

Idea principal

In hypertensive UK adults followed up to 21 years, visit-to-visit systolic blood pressure variability predicted cardiovascular events independent of average pressure (HR 1.22 per 5 mmHg), and amlodipine-based treatment beat atenolol-based for stroke (HR 0.82). The claim that variability mediated the benefit rests on post-trial observational modeling.

Study design

Artículo de investigación

Reading basis

Published abstract

Reading focus

Design & applicability

Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.

Pregunta de investigación

Blood pressure that swings between visits predicts heart events, but it is unclear how a period of control with different variability affects long-term outcomes. The authors extended ASCOT-BPLA follow-up to see how average pressure and variability during the trial related to later events.

Población y método

Extended follow-up of UK participants in ASCOT-BPLA: hypertensive adults (4305 assigned to amlodipine with or without perindopril, 4275 to atenolol with or without a diuretic) treated for a median 5.5 years in-trial and followed up to 21 years (median 17.4) via linked hospital and mortality records. A subgroup (n = 2156) was followed 6 years after trial closure with a questionnaire and clinic visit. In-trial mean systolic blood pressure (SBP) and the standard deviation of visit-to-visit SBP (variability) came from over 100,000 measurements. Cox models estimated hazard ratios for in-trial pressure and variability against post-trial events, and for assigned treatment against pre-specified outcomes.

Resultados

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Mean in-trial SBP predicted later cardiovascular events (HR 1.14 per 10 mmHg, 95% CI 1.10-1.17, P < .001), but systolic variability independent of the mean was a strong predictor (HR 1.22 per 5 mmHg, 95% CI 1.18-1.26, P < .001), even in people with well-controlled pressure.
  2. 2
    Over 21 years, amlodipine-based compared with atenolol-based treatment lowered stroke (HR 0.82, 95% CI 0.72-0.93, P = .003), total cardiovascular events (HR 0.93, 0.88-0.98, P = .008), total coronary events (HR 0.92, 0.86-0.99, P = .024) and atrial fibrillation (HR 0.91, 0.83-0.99, P = .030).
  3. 3
    Cardiovascular mortality showed weaker evidence of a difference (HR 0.91, 95% CI 0.82-1.01, P = .073).
  4. 4
    There was no significant difference in non-fatal myocardial infarction and fatal coronary heart disease, heart failure or all-cause mortality.

Límites e incertidumbre

  1. 1
    The conclusion that variability mediates the drug difference comes from statistical modeling, and mediation cannot be proven in this design.
  2. 2
    Variability was measured from clinic visits during trial years, not from home or ambulatory monitoring, and participants were hypertensive UK adults.
  3. 3
    Atenolol-based treatment is an older regimen, so the comparison may not reflect current first-line choices.
  4. 4
    Many outcomes were tested, so some P values near .03 could be chance. This reading rests on the abstract only.

Relevancia práctica

Stable readings across visits appear to matter in addition to a good average, which is a reason to keep measurements consistent, not to chase single numbers. These results do not mean any one drug should be swapped; treatment choices belong with your clinician.

Tus datos

A home blood pressure cuff lets you see variability over weeks: measure at the same times, with the same cuff and posture, and share the log with your clinician. Home readings are not identical to the clinic readings used here, and wrist or watch estimates are less reliable.

Cómo interpretar la evidencia

The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.

Resumen estructurado de los autores English

El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.

Background and aims

Visit-to-visit systolic blood pressure variability (BPV) is an important predictor of cardiovascular (CV) outcomes. The long-term effect of a period of blood pressure (BP) control, but with differential BPV, is uncertain. Morbidity and mortality follow-up of UK participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm has been extended for up to 21 years to determine the CV impact of mean systolic blood pressure (SBP) control and BPV during the trial, and amongst those allocated to amlodipine- and atenolol-based treatment.

Methods

Eight thousand five hundred and eighty hypertensive participants (4305 assigned to amlodipine ± perindopril-based and 4275 to atenolol ± diuretic-based treatment during the in-trial period (median 5.5 years) were followed for up to 21 years (median 17.4 years), using linked hospital and mortality records. A subgroup of participants (n = 2156) was followed up 6 years after the trial closure with a self-administered questionnaire and a clinic visit. In-trial mean SBP and standard deviation of visit-to-visit SBP as a measure of BPV, were measured using >100 000 BP measurements. Cox proportional hazard models were used to estimate the risk [hazard ratios (HRs)], associated with (i) mean with SBP and BPV during the in-trial period, for the CV endpoints occurring after the end of the trial and (ii) randomly assigned treatment to events following randomization, for the first occurrence of pre-specified CV outcomes.

Results

Using BP data from the in-trial period, in the post-trial period, although mean SBP was a predictor of CV outcomes {HR per 10 mmHg, 1.14 [95% confidence interval (CI) 1.10-1.17], P < .001}, systolic BPV independent of mean SBP was a strong predictor of CV events [HR per 5 mmHg 1.22 (95% CI 1.18-1.26), P < .001] and predicted events even in participants with well-controlled BP. During 21-year follow-up, those on amlodipine-based compared with atenolol-based in-trial treatment had significantly reduced risk of stroke [HR 0.82 (95% CI 0.72-0.93), P = .003], total CV events [HR 0.93 (95% CI 0.88-0.98), P = .008], total coronary events [HR 0.92 (95% CI 0.86-0.99), P = .024], and atrial fibrillation [HR 0.91 (95% CI 0.83-0.99), P = .030], with weaker evidence of a difference in CV mortality [HR 0.91 (95% CI 0.82-1.01), P = .073]. There was no significant difference in the incidence of non-fatal myocardial infarction and fatal coronary heart disease, heart failure, and all-cause mortality.

Conclusions

Systolic BPV is a strong predictor of CV outcome, even in those with controlled SBP. The long-term benefits of amlodipine-based treatment compared with atenolol-based treatment in reducing CV events appear to be primarily mediated by an effect on systolic BPV during the trial period.

Fuentes y atribución

Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial.

Gupta A, Whiteley WN, Godec T, Rostamian S, Ariti C, Mackay J, Whitehouse A, Janani L, Poulter NR, Sever PS, ASCOT-10 Investigators .

European heart journal · 2024-04-01

DOI: 10.1093/eurheartj/ehad814 ↗PubMed · 38291599 ↗Europe PMC · Licencia registrada: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada

Fuentes verificadas 2026-11-01

Guías prácticas

Leer en contexto

·Metaanálisis observacional

Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people

Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.

Journal of the American Heart Association

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Five exercise types lowered resting blood pressure, isometric training the most

Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Ensayo aleatorizado

A salt substitute lowered stroke, major cardiovascular events and death in rural China

In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.

The New England Journal of Medicine

Explicaciones detalladasLeer estudio →
·Estudio/revisión de validación

Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation

Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.

The New England Journal of Medicine

Explicaciones detalladasLeer estudio →
Salud cardiovascular →